ClinicalTrials.gg
CompletedNCT00004583Updated Feb 20, 2009

A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy

A Phase 3 interventional study of Lopinavir/Ritonavir and Nelfinavir mesylate in HIV Infections, sponsored by Abbott. Completed at 83 sites in 14 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2009-02-20.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
660
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies testing nelfinavir in HIV Infections — none open to participants now, none under way, none of them phase 3. Nelfinavir · HIV Infections.

Enrollment
5th of 37
660 · median 103
Started
1999
with 4 others
Phase 3
9 of 45
none open now
Registered
1st of 45
by date
Lead sponsor
2 of 45
Abbott

Among the 45 studies testing nelfinavir in HIV Infections, this one is the 5th largest by enrollment of the 37 interventional ones that give a count, is one of 5 that started in 1999, is one of 9 in phase 3, and was the 1st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 45 studies testing nelfinavir in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About nelfinavir

Nelfinavir: first FDA approval 1997 (VIRACEPT), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 45 studies testing nelfinavir in HIV Infections as a file.
02

Study summary

The purpose of this study is to see how safe a new protease inhibitor (PI) is and how well it fights HIV infection. A PI is a drug that stops HIV from using healthy cells to make more virus. This study will compare the new PI combination of ABT-378 plus ritonavir (RTV) with another PI, nelfinavir (NFV).

Earlier studies suggest ABT-378/RTV will be just as good as and perhaps better than NFV at fighting HIV infection.

Read the detailed description

Based on the accumulated studies to date, it is expected that ABT-378/ritonavir will provide efficacy that is at least as good as (or superior to) nelfinavir when used in combination with reverse transcriptase inhibitors.

Patients are equally randomized to one of two treatment arms. In one arm, approximately 330 patients receive ABT-378/ritonavir plus nelfinavir placebo. In the other arm, approximately 330 patients receive nelfinavir plus ABT-378/ritonavir placebo. In both arms, these protease inhibitors are blinded to the investigator, patient, and sponsor. Both arms receive open-label stavudine and lamivudine. Vital sign measurements, physical examinations, ECGs, routine clinical laboratory evaluations, and determinations of antiviral and immunologic activity are performed at intervals throughout the study.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Drug Therapy, Combination
  • Administration, Oral
  • Stavudine
  • HIV Protease Inhibitors
  • Lamivudine
  • Reverse Transcriptase Inhibitors
  • Anti-HIV Agents
  • Nelfinavir
  • ABT 378
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

You may be eligible for this trial if you:

  • Are positive.
  • Have a viral load (level of HIV in your blood) of more than 400 copies/ml.
  • Are age 12 or older.
  • Agree to practice abstinence or use effective methods of during the study.

Exclusion criteria

Exclusion Criteria

You will not be eligible for this trial if you:

  • Have taken anti- drugs for more than 14 days in the past, or if you have ever taken d4T or 3TC.
  • Are seriously ill or have an AIDS-related infection.
  • Are pregnant or breast-feeding.
  • Are taking certain medications.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Masking
Double
Enrollment
660 participants

Interventions

06

Study locations

83 sites
  • Pacific Oaks Med Group
    Beverly Hills, California 90211, United States
  • Orange County Ctr for Special Immunology
    Fountain Valley, California 92708, United States
  • AIDS Healthcare Foundation
    Los Angeles, California 900276069, United States
  • Tower ID Med Associates
    Los Angeles, California 90048, United States
  • UCLA CARE Ctr
    Los Angeles, California 90095, United States
  • San Francisco Veterans Administration Med Ctr
    San Francisco, California 94121, United States
  • Harbor - UCLA Med Ctr
    Torrance, California 90502, United States
  • Yale Univ / AIDS Clinical Trials Unit
    New Haven, Connecticut 06510, United States
  • Steinhart Medical Associates
    Miami, Florida 33133, United States
  • Univ of Miami School of Medicine
    Miami, Florida 33136, United States
  • Infectious Disease Research Institute
    Tampa, Florida 33614, United States
  • AIDS Research Consortium of Atlanta
    Atlanta, Georgia 30308, United States
  • Emory Univ
    Atlanta, Georgia 30308, United States
  • AIDS Research Alliance - Chicago
    Chicago, Illinois 60657, United States
  • Division of Inf Diseases/ Indiana Univ Hosp
    Indianapolis, Indiana 46202, United States
  • Univ of Kansas School of Medicine
    Wichita, Kansas 67214, United States
  • Tulane Univ Med School
    New Orleans, Louisiana 70112, United States
  • Johns Hopkins Hosp
    Baltimore, Maryland 21205, United States
  • Boston Med Ctr
    Boston, Massachusetts 02118, United States
  • Community Research Initiative of New England
    Brookline, Massachusetts 02445, United States
  • Univ of Michigan Hospitals and Health Ctrs
    Ann Arbor, Michigan 481090378, United States
  • Abbott Northwestern Hosp
    Minneapolis, Minnesota 55407, United States
  • East Orange Veterans Administration Med Ctr
    East Orange, New Jersey 07018, United States
  • Beth Israel Med Ctr
    New York, New York 10003, United States
  • Cornell Clinical Trials Unit - Chelsea Clinic
    New York, New York 10011, United States
  • Howard Grossman
    New York, New York 10011, United States
  • SUNY at Stony Brook / Div of Infectious Disease
    Stony Brook, New York 117948153, United States
  • Duke Univ Med Ctr / Infectious Disease Clinic
    Durham, North Carolina 27710, United States
  • Holmes Hosp / Univ of Cincinnati Med Ctr
    Cincinnati, Ohio 452670405, United States
  • Associates in Med and Mental Health
    Tulsa, Oklahoma 74114, United States
  • Oregon Health Sciences Univ
    Portland, Oregon 972109951, United States
  • Philadelphia FIGHT
    Philadelphia, Pennsylvania 19107, United States
  • Stephen Hauptman
    Philadelphia, Pennsylvania 19107, United States
  • The Miriam Hosp
    Providence, Rhode Island 02906, United States
  • Vanderbilt Univ Med Ctr
    Nashville, Tennessee 37203, United States
  • Central Texas Med Foundation
    Austin, Texas 78751, United States
  • Oaklawn Physicians Group
    Dallas, Texas 75219, United States
  • Univ of Texas Southwestern Med Ctr
    Dallas, Texas 75235, United States
  • Joseph C Gathe
    Houston, Texas 77004, United States
  • Infectious Disease Physicians Inc
    Annandale, Virginia 22203, United States
  • Univ of Virginia Health Sciences Ctr
    Charlottesville, Virginia 22908, United States
  • Univ of Wisconsin
    Madison, Wisconsin 53792, United States
  • Royal Brisbane Hosp
    Herston, Australia
  • Royal Perth Hosp
    Perth, Australia
  • Alfred Hosp
    Prahan, Australia
  • Pulmologisches Zentrum Der Stadt Wien
    Wien, Austria
  • Hosp Evandro Chagas Fioernz
    Manguinhos RJ, Brazil
  • Castelo
    Sao Paulo, Brazil
  • Fundacao Zerbini Casa Da Aids
    Sao Paulo, Brazil
  • Hosp Do Servidor Publico Estadual De Sao Paulo
    Sao Paulo, Brazil
  • Hosp Heliopolis
    Sao Paulo, Brazil
  • Saint Paul's Hosp
    Vancouver, British Columbia, Canada
  • Ottawa General Hospital
    Ottawa, Ontario, Canada
  • Toronto Gen Hosp
    Toronto, Ontario, Canada
  • Clinique Medicale du Quartier Latin
    Montreal, Quebec, Canada
  • Clinique Medicale L'Actuele
    Montreal, Quebec, Canada
  • Montreal Chest Institute
    Montreal, Quebec, Canada
  • Righospitalet
    Copenhagen, Denmark
  • Hvidovre Univ Hosp
    Hvidovre, Denmark
  • Centre Hospitalier De Compiegne
    Compiegne, France
  • Groupe Hospitalier Bichat-Claude Bernard
    Paris Cedex 18, France
  • CHU De Bicetre
    Paris, France
  • Hopital Paul Brousse
    Villejuif, France
  • EPIMED
    Berlin, Germany
  • Heinrich Heine Universitat
    Dusseldorf, Germany
  • Klinikum Der Johann Wolfgang Goethe Universitat
    Frankfurt, Germany
  • Allgemeines Krankenhaus St Georg
    Hamburg, Germany
  • Univ Zu Koeln
    Koeln, Germany
  • Ctr of AIDS Diagnosis and Treatment
    Warszawa, Poland
  • Clinical Research Puerto Rico Inc
    San Juan, 00909, Puerto Rico
  • Miller
    Belford Gardens, South Africa
  • Cyrildene
    Johannesburg, South Africa
  • Wits Medical School
    Parktown, South Africa
  • Hosp Germans Trias I Pujol
    Barcelona, Spain
  • Hosp Carlos III
    Madrid, Spain
  • Hosp De Mostoles
    Madrid, Spain
  • Hosp Doce De Octubre
    Madrid, Spain
  • Hosp La Paz
    Madrid, Spain
  • Hosp Virgen Del Rocio
    Sevilla, Spain
  • Universitatsspital Zurich
    Zurich, Switzerland
  • Brighton Gen Hosp
    Brighton, United Kingdom
  • Imperial College School of Medicine
    London, United Kingdom
  • Royal Free Hosp
    London, United Kingdom
07

References and documents

Publications

  • Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, White AC Jr, Benson C, Thompson M, Kessler HA, Hammer S, Bertz R, Hsu A, Japour A, Sun E. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 2001 Jan 5;15(1):F1-9. doi: 10.1097/00002030-200101050-00002. PubMed 11192874 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 20, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00004583
Lead sponsor
Abbott
First posted
Aug 31, 2001
Start date
Mar 1999
Last update
Feb 20, 2009
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nelfinavir · Lamivudine · Stavudine

Start the discussion